gvtcx

Requirement for producer cell line for GMP viral vector packaging

NHS Blood and Transplant (NHSBT) Published 13 Apr 2022 Contracts Finder

key details

Value£111,000
Statuscomplete
Category (CPV) 33141000
Deadline3 Jun 2020
Contract start7 Apr 2022
Contract end5 Apr 2024
Procedureopen
SME suitableNo
OCIDocds-b5fd17-3fd467a5-e5f9-42c6-9584-4a41fa5faa04

Award

SupplierValueDateStatus
LIFE TECHNOLOGIES LIMITED £111,000 6 Apr 2022 active

description

NHSBT's Clinical Biotechnology Centre for the purpose of specifying the user requirement for HEK293-derived production cell line for the GMP-production of viral vectors and other recombinant proteins. The CBC has an MHRA licence for the manufacture of investigational medicinal gene therapy and recombinant protein products for use in clinical trials. In order to manufacture GMP-grade viral vectors and recombinant proteins for clinical trials, a GMP-qualified producer cell line is required.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
13 Apr 2022 Award (award) · 4e846bf1-37bd-4aca-8807-356ca5ac9b40-528427

more from NHS Blood and Transplant (NHSBT)

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.